Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

If you have chronic inflammatory demyelinating polyneuropathy (CIDP), you may have encountered delays and missteps before finally getting diagnosed. Getting the correct diagnosis can be tricky when ...

Argenx (ARGX) announced an update on their ongoing clinical study. Argenx is currently recruiting participants for a study titled ‘Real-World Efgartigimod Effectiveness in CIDP: A Prospective Study’.

Chinese scientists reveal the feasibility, tolerability, and efficacy of BCMA-CD19 bispecific CAR T-cells for treating chronic inflammatory demyelinating polyneuropathy (CIDP) and highlight the ...

The growth of the chronic inflammatory demyelinating polyneuropathy market is expected to be primarily driven by an expanding diagnosed patient population, improved disease awareness and diagnostic ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...

PHOENIX — Subcutaneous efgartigimod PH20 SC shows efficacy and tolerability in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), providing a convenient alternative to ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) diagnoses are frequently missed or delayed and standard treatments -- intravenous immunoglobulin (IVIG), steroids, and plasma exchange -- are ...

Standard treatment for many autoimmune diseases includes drugs that suppress the immune system. Even when this approach works (and it doesn’t work for everyone), chronic immunosuppression puts ...

Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration ...

A blockbuster Argenx therapy now has an additional FDA approval as a treatment for a rare autoimmune disorder affecting nerves, marking the first new treatment for this condition in decades and a new ...